piperidolate hydrochloride

Piperidolate hydrochloride is a synthetic tertiary amine antimuscarinic and anticholinergic agent. It acts as a competitive antagonist at muscarinic acetylcholine receptors (M1 through M5), thereby blocking the action of acetylcholine on smooth muscle cells. By inhibiting parasympathetic stimulation, piperidolate hydrochloride reduces involuntary muscle contractions and spasms in the gastrointestinal tract and the uterus, and also exhibits mild antisecretory properties. Originally developed by Lakeside Laboratories and approved in the United States in 1954, it is no longer marketed there but remains approved and used in other regions, particularly Japan (marketed by Kissei as Dactil) and Taiwan (marketed by Kyorin as Dactiran). It is primarily indicated for the relief of cramp-like pain associated with gastrointestinal disorders (such as gastric and duodenal ulcers, gastritis, enteritis, cholelithiasis, cholecystitis, and biliary dyskinesia) and for the management of threatened abortion or threatened premature labor by suppressing abnormal uterine contractions. Additionally, it has been investigated for reducing uterine contractions during the implantation period in patients with recurrent implantation failure.

Brand names

CrapinonDactilDactiranLicosShinlin

Other names

1-ethyl-3-piperidyl diphenylacetate hydrochloride1-ethylpiperidin-3-yl diphenylacetate hydrochlorideEdelelEdelel hydrochlorideN-ethyl-3-piperidyl diphenylacetate hydrochlorideN-ethyl3-piperidyl diphenylacetate hydrochlorideN-ethyl 3-piperidyl diphenylacetate hydrochloridediphenylacetic acid 1-ethyl-3-piperidinyl ester hydrochloridediphenylacetic acid 1-ethyl-3-piperidyl ester hydrochloridepiperidolatepiperidolate HClpiperidolate hydrochloridepiperidolatopiperidolatum